<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345043</url>
  </required_header>
  <id_info>
    <org_study_id>VAL-339851-P101</org_study_id>
    <nct_id>NCT03345043</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of VAL-339851 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moderna Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moderna Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will assess the safety, tolerability and immunogenicity of VAL-339851 in
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 25, 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of solicited AEs (local and systemic reactogenicity events)</measure>
    <time_frame>7 days following each dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of unsolicited adverse events</measure>
    <time_frame>21 days following each dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of serious adverse events (SAE), adverse events of special interest (AESI), medically-attended AEs, and new onset of chronic illness</measure>
    <time_frame>One year after last dose administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Titers of hemagglutinin inhibition (HAI) and microneutralization antibodies in comparison with baseline sample</measure>
    <time_frame>One year after last dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rates in comparison to baseline samples</measure>
    <time_frame>One year after last dose administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>VAL-339851</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VAL-339851</intervention_name>
    <description>Escalating dose levels</description>
    <arm_group_label>VAL-339851</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agrees to comply with the study procedures and provides written informed consent

          -  18 to 49 years of age

          -  Body mass index between 18 and 35 kg/m2

          -  Negative urine pregnancy test at the Screening visit and the day of each vaccination
             for females of childbearing potential.

          -  Female subjects must either be of non-childbearing potential or use acceptable methods
             of contraception from at least 3 weeks prior to enrollment and through the end of
             study visit

          -  In good health based on medical history, physical examination, vital sign measurements
             and laboratory safety tests performed prior to initial study vaccination

          -  Has access to a consistent and reliable means of telephone contact and agrees to stay
             in contact with the study site for the duration of the study

        Exclusion Criteria:

          -  Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care

          -  Administration of another investigational product within 60 days, or 5 half-lives,
             whichever is longer

          -  Participation in an investigational study involving lipid nanoparticles

          -  A history of hypersensitivity or serious reactions to previous influenza vaccinations

          -  History of Guillain-Barr√© Syndrome within 6 weeks following a previous influenza
             vaccine

          -  History of narcolepsy

          -  Administration of any licensed (inactivated or live) vaccines within 4 weeks before
             enrollment or plans to receive any vaccine within 12 weeks of the last study drug
             administration; receipt of any other avian H7N9 influenza vaccine at any time prior to
             or during the study is exclusionary

          -  Any known or suspected immunosuppressive condition, acquired or congenital, as
             determined by history and/or physical examination.

          -  Any chronic administration of immunosuppressant or other immune-modifying drugs within
             6 months prior to administration of study vaccine

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the administration of the study vaccine or during the study.

          -  Any acute disease at the time of enrollment

          -  Any significant disorder of coagulation requiring ongoing or intermittent treatment

          -  Active neoplastic disease or a history of any hematologic malignancy

          -  History of alcohol abuse or drug addiction within 1 year before the planned day of
             dose administration

          -  A positive test result for drugs of abuse or alcohol at screening or before the first
             dose administration

          -  Persons employed in a capacity that involves handling poultry or wild birds.

          -  The subject has any abnormality or permanent body art (eg, tattoo) that, in the
             opinion of the investigator, would obstruct the ability to observe local reactions at
             the injection site

          -  Any condition, that in the opinion of the Investigator would pose a health risk to the
             subject if enrolled or could interfere with evaluation of the vaccine or
             interpretation of the study results

          -  A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or
             human immunodeficiency virus types 1 or 2 antibodies at screening

          -  Donation of blood or blood products &gt; 450 mL within 30 days of dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VAL-339851</keyword>
  <keyword>H7N9 antigen mRNA</keyword>
  <keyword>Influenza vaccine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

